Literature DB >> 7684788

Microbiology of cystic fibrosis lung infections: themes and issues.

J R Govan1, J W Nelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7684788      PMCID： PMC1293798     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  71 in total

1.  Pseudomonas cepacia infection in cystic fibrosis.

Authors:  D L Smith; E G Smith; L B Gumery; D E Stableforth
Journal:  Lancet       Date:  1992-01-25       Impact factor: 79.321

2.  Pseudomonas cepacia in inpatients with cystic fibrosis.

Authors:  J W Nelson; C J Doherty; P H Brown; A P Greening; M E Kaufmann; J R Govan
Journal:  Lancet       Date:  1991-12-14       Impact factor: 79.321

3.  Longitudinal serum IgG response to Pseudomonas cepacia surface antigens in cystic fibrosis.

Authors:  S C Aronoff; F J Quinn; R C Stern
Journal:  Pediatr Pulmonol       Date:  1991

4.  Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro.

Authors:  J R Govan; J A Fyfe
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

5.  Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source.

Authors:  W Beckman; T G Lessie
Journal:  J Bacteriol       Date:  1979-12       Impact factor: 3.490

6.  IgA and IgG antibodies against surface antigens of Pseudomonas aeruginosa in sputum and serum from patients with cystic fibrosis.

Authors:  P O Schiøtz; N Høiby; H Permin; A Wiik
Journal:  Acta Pathol Microbiol Scand C       Date:  1979-06

7.  Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis.

Authors:  G Gladman; P J Connor; R F Williams; T J David
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

8.  Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis.

Authors:  U S Sajjan; M Corey; M A Karmali; J F Forstner
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

9.  Immune complexes and humoral response to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  R B Moss; N J Lewiston
Journal:  Am Rev Respir Dis       Date:  1980-01

10.  Role of pili in adherence of Pseudomonas aeruginosa to mammalian buccal epithelial cells.

Authors:  D E Woods; D C Straus; W G Johanson; V K Berry; J A Bass
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441
View more
  17 in total

1.  Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients. The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group.

Authors:  S Whittier; K Olivier; P Gilligan; M Knowles; P Della-Latta
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

2.  Pseudomonas cepacia.

Authors:  C J Taylor; R Howden; T Smith; R C Spencer
Journal:  Arch Dis Child       Date:  1994-04       Impact factor: 3.791

Review 3.  Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation.

Authors:  R S Smith; T J Smith; T M Blieden; R P Phipps
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

4.  Combination of 16S rRNA variable regions provides a detailed analysis of bacterial community dynamics in the lungs of cystic fibrosis patients.

Authors:  Melissa S Doud; Michael Light; Gisela Gonzalez; Giri Narasimhan; Kalai Mathee
Journal:  Hum Genomics       Date:  2010-02       Impact factor: 4.639

5.  Transmissibility and infection control implications of Burkholderia cepacia in cystic fibrosis.

Authors:  S K Fung; H Dick; H Devlin; E Tullis
Journal:  Can J Infect Dis       Date:  1998-05

6.  Heterogeneity of Pseudomonas aeruginosa in Brazilian cystic fibrosis patients.

Authors:  S Silbert; A L Barth; H S Sader
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

7.  Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection.

Authors:  Jean-Francois Marier; Jean Lavigne; Murray P Ducharme
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

8.  Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom.

Authors:  F E Clode; M E Kaufmann; H Malnick; T L Pitt
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

9.  Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.

Authors:  C Beaulac; S Clément-Major; J Hawari; J Lagacé
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 10.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.